Freenome (FRNM)
Blood-based cancer screening built on multiomic, AI-driven detection.
Something off on this page? Send us feedback.
Develops blood-based cancer-screening tests, beginning with FDA-approved SimpleScreen CRC, while advancing a multiomic AI/ML platform for lung and other indications through partner-led commercialization and retained testing rights.
Develops blood-based early-cancer-screening tests through a multiomics and AI/ML platform that combines cell-free DNA methylation, other biomarkers, and computational models. FDA-approved SimpleScreen CRC screens average-risk adults for colorectal cancer, and a positive result requires follow-up colonoscopy. SimpleScreen Lung remains under clinical evaluation, while Personalized Cancer Detection supports additional single- and multi-cancer programs.
Licenses standalone U.S. colorectal-cancer commercialization to Abbott, performs initial test processing, analysis, and return of results, and retains U.S. combination and multi-cancer rights. Roche holds exclusive rights to develop decentralized kitted tests outside the United States, while centralized testing rights are retained internationally. Launch economics depend on partner execution, payer reimbursement, provider adoption, follow-up colonoscopy, and clinical and regulatory progress.
Company facts
No analyst consensus on record.
EPSReportedEstimate
RevenueReportedEstimate
Not reported.
No dividends on record.
| Insiders | 47.98% | 3.91M shares | |
|---|---|---|---|
| 10 holders · as of Sep 4, 2026 | |||
| Strategic holders | 28.84% | 2.35M shares | |
| 1 holder · as of Jul 23, 2026 | |||
| Other | 23.18% | 1.89M shares | |
| remainder | |||
8.16M company shares as of Aug 21, 2026 · holders as of their latest filing
The share count has not been confirmed by a second filing; stakes use it as it stands.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
Riley Charles EnnisInsiderofficer: Chief Product Officer | 35.11% | 2.86M | filed Jul 27, 2026 |
Perceptive Capital Solutions HoldingsStrategicother: Former 10% Owner | 28.84% | 2.35M | filed Jul 23, 2026 |
Cheng-Ho Jimmy LinInsiderofficer: Chief Scientific Officer | 5.03% | 410,154 | filed Jul 27, 2026 |
Aaron Matthew ElliottInsiderdirector, officer: Chief Executive Officer | 4.24% | 345,976 | filed Sep 4, 2026 |
Randal W. ScottInsiderdirector | 1.28% | 104,204 | filed Jul 27, 2026 |
Insider tradesForm 4
No open-market trades in the last 12 months.
- Guardant Health
Shield directly contests blood-based colorectal cancer screening.
- Abbott
Cologuard and Cancerguard provide CRC and multi-cancer alternatives.
- GRAIL
Galleri targets multi-cancer detection in shared preventive-screening workflows.
- Caris Life Sciences
Caris Detect broadens blood-based multi-cancer screening competition.
- Natera
A CRC early-detection program overlaps in blood-based assay development.
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Freenome | $16.65 | +0.30% | $135.4M | — | — | — | — |
| Guardant Health | $177.45 | +2.06% | $23.33B | — | — | 19.7 | +44.3% |
| Abbott | $104.33 | +1.31% | $178.18B | 33.1 | 18.0 | 3.8 | +13.0% |
| GRAIL | $110.08 | +1.95% | $4.63B | — | — | 28.0 | +25.7% |
| Caris Life Sciences | $31.83 | +3.84% | $8.66B | 85.6 | 126.4 | 8.8 | +45.4% |
| Natera | $390.11 | +5.25% | $53.08B | — | — | 19.6 | +37.7% |
| Median | 59.4 | 72.2 | 19.6 | +37.7% |